CVS Health Co. (NYSE:CVS - Get Free Report) shares dropped 1.2% during trading on Monday after Barclays lowered their price target on the stock from $82.00 to $79.00. Barclays currently has an overweight rating on the stock. CVS Health traded as low as $63.09 and last traded at $63.28. Approximately 1,356,763 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 11,174,638 shares. The stock had previously closed at $64.04.
CVS has been the subject of a number of other reports. Cowen restated a "buy" rating on shares of CVS Health in a report on Monday, May 5th. JPMorgan Chase & Co. increased their price objective on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday, February 18th. UBS Group increased their price objective on CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Wolfe Research increased their price objective on CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Finally, Mizuho increased their price objective on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $74.75.
Read Our Latest Analysis on CVS Health
Insiders Place Their Bets
In other news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.22% of the company's stock.
Institutional Trading of CVS Health
Large investors have recently made changes to their positions in the company. Whitebox Advisors LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at about $249,000. B&D White Capital Company LLC acquired a new position in CVS Health during the 4th quarter valued at about $417,000. Fairfax Financial Holdings Ltd. Can acquired a new position in CVS Health during the 4th quarter valued at about $121,742,000. Lazard Asset Management LLC boosted its stake in CVS Health by 7.3% during the 4th quarter. Lazard Asset Management LLC now owns 4,290,953 shares of the pharmacy operator's stock valued at $192,617,000 after purchasing an additional 293,406 shares during the last quarter. Finally, Seizert Capital Partners LLC boosted its stake in CVS Health by 22.8% during the 4th quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator's stock valued at $25,566,000 after purchasing an additional 105,708 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.
CVS Health Price Performance
The firm has a market cap of $80.48 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The business has a 50 day simple moving average of $65.54 and a 200-day simple moving average of $59.74.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.31 EPS. Equities research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.
CVS Health Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.18%. CVS Health's payout ratio is presently 63.48%.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
